ASH: Gilead­'s Kite un­veils more da­ta on Yescar­ta's win in sec­ond-line lym­phoma pa­tients, set­ting up bat­tle for SOC

As a spate of re­searchers work dili­gent­ly on next-gen CAR-T cell ther­a­pies, the big play­ers in the cur­rent gen­er­a­tion of those drugs are still an­gling for more mar­ket share. Get­ting to pa­tients ear­li­er is now the game plan, and Gilead’s Kite has un­corked some im­pres­sive da­ta back­ing up its case in lym­phoma.

Kite’s Yescar­ta (axi­cab­ta­gene ciloleu­cel) cut the risk of dis­ease pro­gres­sion, death or the need for ad­di­tion­al ther­a­py by a lit­tle more than 60% com­pared with stan­dard of care in sec­ond-line pa­tients with re­lapsed or re­frac­to­ry large B cell lym­phoma, ac­cord­ing to full da­ta from the Phase III ZU­MA-7 study re­vealed Sat­ur­day at #ASH21.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN